Items tagged with Scientific research
Scientists figure out molecular mechanism behind latent TB (post)
Tuberculosis infection results in approximately nine million new cases worldwide every year. TB-causing bacterium can remain dormant in human body for a long time, even for several decades before it becomes infectious. The bacterium remains ensconced within a type of white blood cells called macrophages, when it is in its latent form.
First impressions go a long way in the immune system (post)
First impressions are important -- they can set the stage for the entire course of a relationship. The same is true for the impressions the cells of our immune system form when they first meet a new bacterium. Using this insight, Weizmann Institute of Science researchers have developed an algorithm that may predict the onset of such diseases as tuberculosis. The findings of this research were recently published in Nature Communications.
Old vaccine brings new surprises (post)
New research about an old vaccine – one that has been in use for nearly 100 years – has not only shown how effective it is but also suggests it improves our immune response to a wider range of bacteria than originally intended.
Waking up sleeping bacteria to fight infections (post)
Researchers in the group of Jan Michiels (VIB-KU Leuven Center for Microbiology) identified a mechanism of how sleepy bacteria wake up. This finding is important, as sleepy cells are often responsible for the stubbornness of chronic infections. Findings published in Molecular Cell reveal new perspectives on how to treat chronic infections, for example by forcing bacteria to wake up.
New study reveals how TB bacteria may survive in human tissues (post)
Carbon monoxide is an infamous and silent killer that can cause death in minutes. But while it is deadly for us, some microorganisms actually thrive on it, by using this gas as an energy source.
Thermally-stable TB vaccine closer to reality thanks to microscopic silica cages (post)
Scientists working on a new tuberculosis (TB) vaccine have achieved a major step forward by showing that a promising TB antigen and a novel vaccine adjuvant can be protected from heat damage with a technique developed at the University of Bath.
Lung lining fluid key to elderly susceptibility to TB infection (post)
Old lungs are not as capable as young lungs of fighting off an infection of the bacteria that causes tuberculosis (TB), placing seniors at a greater risk of developing TB. The microbe that causes this infectious disease, Mycobacterium tuberculosis (Mtb), currently kills more people in the world than any other pathogen.
Study maps genetics of early progression in TB (post)
While the vast majority of the 1.8 billion people infected with the TB bacterium never experience active disease, an estimated 5 to 15 percent do develop full-blown infections—roughly half of them within 18 months of exposure.
TB mutation discovery paves way for better treatments (post)
PNAS publishes Rutgers New Jersey Medical school study: 'Phase variation in Mycobacterium tuberculosis glpK produces transiently heritable drug tolerance'.
BioNTech announces new collaboration to develop HIV and TB programs (post)
Mainz, Germany, September 4, 2019 – BioNTech SE, a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, announced today that it has signed an agreement with the Bill & Melinda Gates Foundation (the Gates Foundation) to develop HIV and tuberculosis programs, further expanding the Company’s infectious disease portfolio. This partnership includes an initial equity investment of $55 million, which is expected to close within the next week. The funds will be used to develop preclinical vaccine and immunotherapy candidates to prevent HIV and tuberculosis infection as well as to lead to durable antiretroviral therapy-free remission of HIV disease. Total funding under the collaboration could reach $100 million through potential future grant funding from the Gates Foundation that would be used to underwrite the evaluation of these candidates in the clinic and support the initiation of new infectious disease projects.
Page 42 of 74 · Total posts: 0
←First 41 42 43 Last→